Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
|Slideshows|December 26, 2017
Statins and Risk of Parkinson Disease
Author(s)Veronica Hackethal, MD
There has been long-running controversy regarding the association between statins and PD risk. Two studies with conflicting results are examined here.
Advertisement
Advertisement
Related to this article
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
2
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
3
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
4
PrimeC Lowers Neuron-Derived TDP-43, Informing Phase 3 PARAGON Trial in ALS
5